Hysteroscopic resection of symptomatic sub mucosal myomas with the use of bipolar energy

Hysteroscopic resection of symptomatic sub mucosal myomas with the use of monopolar energy

Symptomatic Submucosal Myoma

Hysteroscopic resection with bipolar energy

Hysteroscopic resection with monopolar energy

CHU Brugmann

CHU Bicêtre, Kremlin Bicêtre

Comparing Intra Uterine Synechiae Occurence Using Bipolar Energy Compared With Monopolar Energy in Myoma Resection on Women Having Menorraghia and/or Infertility

MONOBISY: Randomized Controlled Trial Comparing Intra Uterine Synechiae Occurence Using Bipolar Energy Compared With Monopolar Energy in Myoma Resection on Women Having Menorraghia and/or Infertility

The main goal of this study is to compare the rate of uterine adhesions six weeks after the hysteroscopic surgical treatment of sub mucosal uterine myomas, in a group where bipolar energy is used versus a group where monopolar energy is used during the surgery. Outcome measured at the diagnostic hysteroscopic visit, 6 weeks after surgery.

Number of evolutive pregnancies - phone contact 18 months after surgery

Number of spontaneous abortions - phone contact 18 months after surgery

Complications rate during the surgery duration

Post-surgery complications rate, measured at the diagnostic hysteroscopic visit performed 6 weeks after surgery.

Andre Nazac

Head of Clinic

Brugmann University Hospital

The patients in the placebo group received equal numbers of identical looking placebo 2 h before operation

Patients in the gabapentin group received two capsules of gabapentin 300 mg (Neurontin®, Pfizer) at 2 h before operation.

Pruritus

Gabapentin

Songklanagarind Hospital

Gabapentin for Prophylaxis Intrathecal Morphine-Induced Pruritus

Gabapentin for Prophylaxis Intrathecal Morphine-Induced Pruritus After Orthopedics Surgery

the incidence of pruritus during the 24 h follow-up period

The difference of onset time and severity of pruritus in the gabapentin and placebo groups

maliwan oofuvong

Assistant Professor

Prince of Songkla University

Concurrent chemoradiation Therapy:
Radiation therapy:2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks.
Temozolomide from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days.
Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle,at the beginning of the 4th week of radiation. The dose will be 10 mg/kg.
Adjuvant Therapy:
Temozolomide once per day for 5 consecutive days of a cycle. The starting dose for the first cycle will be 150 mg/m2/day, with a single dose 200 mg/m2/day in subsequent cycles if no treatment-related adverse events> grade 2 are noted.
Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle. The dose will be 10 mg/kg.

Glioblastoma

Radiation therapy:For both intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiation therapy (3D-CRT) plans, one treatment of 2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks.
Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days.
Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle,at the beginning of the 4th week of radiation. The dose will be 10 mg/kg of actual body weight.

Chemoradiation Therapy

Temozolomide will be administered orally once per day for 5 consecutive days (days 1-5) of a 28-day cycle. The starting dose for the first cycle will be 150 mg/m2/day, with a single dose escalation to 200 mg/m2/day in subsequent cycles if no treatment-related adverse events> grade 2 are noted.
Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle. The dose will be 10 mg/kg of actual body weight.

Adjuvant Therapy

Shandong Cancer Hospital and Institute

A Explore Study of Bevacizumab Combined With Conventional Therapy in Glioblastoma

An Open-label, Single Arm Study to Explore Whether Potential Image Biomarkers Correlate With Efficacy of Bevacizumab Combined With Conventional Therapy in Newly Diagnosed Glioblastoma

PFS (evaluated by RANO criteria), defined as the interval from start of treatment to investigator-assessed progression or death, whichever occurs first or lost of follow-up.
At Week 10 of the study (corresponding to 7 weeks after the commencement of bevacizumab therapy).

OS is the time interval from the start of treatment to death due to any reason or lost of follow-up.

ORR is the number of responders (CR, PR) vs. the whole study population.Tumor response will be evaluated according to the Response Assessment in Neuro-Oncology (RANO) criteria.

European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30

Safety will be measured based on the NCI-Common Terminology Criteria for Adverse Events (NCI-CTCAE), v4.0

glycine/edema

Comparing Intra Uterine Synechiae Occurence Using Bipolar Energy Compared With Monopolar Energy in Myoma Resection on Women Having Menorraghia and/or Infertility

Gabapentin for Prophylaxis Intrathecal Morphine-Induced Pruritus

A Explore Study of Bevacizumab Combined With Conventional Therapy in Glioblastoma

Najkompletnija baza ljekovitog bilja potpomognuta naukom